{"id":"lorazepam-mylan","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Sedation/drowsiness"},{"rate":"15-25","effect":"Dizziness"},{"rate":"10-20","effect":"Ataxia/coordination impairment"},{"rate":null,"effect":"Dependence/withdrawal risk"},{"rate":null,"effect":"Respiratory depression"},{"rate":"10-15","effect":"Cognitive impairment"}]},"_chembl":{"chemblId":"CHEMBL580","moleculeType":"Small molecule","molecularWeight":"321.16"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lorazepam is a benzodiazepine that binds to GABA-A receptors and potentiates the effect of the inhibitory neurotransmitter GABA, leading to increased chloride ion influx and neuronal hyperpolarization. This results in sedative, anxiolytic, anticonvulsant, and muscle relaxant effects. The drug is commonly used for acute anxiety, seizure management, and sedation in clinical settings.","oneSentence":"Lorazepam enhances the inhibitory effects of GABA at GABA-A receptors in the central nervous system, reducing neuronal excitability.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:52:57.133Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anxiety disorders"},{"name":"Acute seizures and seizure prophylaxis"},{"name":"Insomnia"},{"name":"Alcohol withdrawal"},{"name":"Preoperative sedation"}]},"trialDetails":[{"nctId":"NCT02078336","phase":"PHASE4","title":"Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2013-12","conditions":"Dental Care for Disabled","enrollment":40},{"nctId":"NCT00649818","phase":"PHASE1","title":"Fasting Study of Lorazepam Tablets 2 mg and Ativan Tablets 2 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2004-12","conditions":"Healthy","enrollment":28}],"_emaApprovals":[],"_faersSignals":[{"count":6,"reaction":"DRUG INEFFECTIVE"},{"count":6,"reaction":"NAUSEA"},{"count":6,"reaction":"SOMNOLENCE"},{"count":5,"reaction":"BRADYCARDIA"},{"count":5,"reaction":"MALAISE"},{"count":4,"reaction":"DIZZINESS"},{"count":4,"reaction":"HEADACHE"},{"count":4,"reaction":"TREMOR"},{"count":4,"reaction":"VOMITING"},{"count":3,"reaction":"CHOLESTASIS"}],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Lorazepam Mylan","genericName":"Lorazepam Mylan","companyName":"Universitaire Ziekenhuizen KU Leuven","companyId":"universitaire-ziekenhuizen-ku-leuven","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lorazepam enhances the inhibitory effects of GABA at GABA-A receptors in the central nervous system, reducing neuronal excitability. Used for Anxiety disorders, Acute seizures and seizure prophylaxis, Insomnia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}